A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
notify the public about an emerging signal concerning 
a medical device in order to reduce or limit the number 
of patients exposed to a potential risk identified based 
on such emerging signal, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Emerging Signals 
4
Modernization Act of 2022’’. 
5
23:09 May 03, 2022
H7646
2 
•HR 7646 IH
SEC. 2. PUBLIC NOTIFICATION OF AN EMERGING SIGNAL 
1
CONCERNING A MEDICAL DEVICE. 
2
(a) TECHNICAL AMENDMENTS.—Section 518 of the 
3
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360h) 
4
is amended— 
5
(1) by striking the section designation and 
6
heading and that follows through ‘‘If the Secretary 
7
determines that—’’ and inserting the following: 
8
‘‘SEC. 518. NOTIFICATION AND OTHER REMEDIES. 
9
‘‘(a) NOTIFICATION.— 
10
‘‘(1) IN GENERAL.—If the Secretary determines 
11
that—’’; and 
12
(2) in subsection (a)— 
13
(A) by striking ‘‘(1) a device’’ and insert-
14
ing the following: 
15
‘‘(A) a device’’; 
16
(B) by striking ‘‘(2) notification’’ and in-
17
serting the following: 
18
‘‘(B) notification’’; 
19
(C) by moving the margin of the continu-
20
ation text at the end of subsection (a) 2 ems to 
21
the right; and 
22
(D) by striking ‘‘this subsection’’ each 
23
place it appears and inserting ‘‘this para-
24
graph’’. 
25
23:09 May 03, 2022
H7646
3 
•HR 7646 IH
(b) EMERGING SIGNALS.—Section 518(a) of the Fed-
1
eral Food, Drug, and Cosmetic Act (21 U.S.C. 360h(a)), 
2
as amended by subsection (a), is further amended by add-
3
ing at the end the following: 
4
‘‘(2) EMERGING SIGNALS AND OTHER NOTIFI-
5
CATIONS.— 
6
‘‘(A) APPLICABILITY.—This paragraph ap-
7
plies if the Secretary— 
8
‘‘(i) determines that a device meets 
9
the conditions described in paragraph 
10
(1)(A), and no more practicable means is 
11
available under the provisions of this Act, 
12
including paragraph (1), to eliminate the 
13
risk described in paragraph (1)(A); or 
14
‘‘(ii) otherwise determines that it is 
15
necessary to notify the public about an 
16
emerging signal concerning a device in 
17
order to reduce or limit the number of pa-
18
tients exposed to a potential risk identified 
19
based on an emerging signal. 
20
‘‘(B) DEFINITION OF EMERGING SIGNAL.— 
21
In this paragraph, the term ‘emerging signal’ 
22
means new information about a marketed de-
23
vice— 
24
23:09 May 03, 2022
H7646
4 
•HR 7646 IH
‘‘(i) that supports a new causal asso-
1
ciation or a new aspect of a known associa-
2
tion between the device and an adverse 
3
event or set of adverse events; and 
4
‘‘(ii) for which the Secretary has con-
5
ducted an initial evaluation and deter-
6
mined that the information has the poten-
7
tial to impact patient management deci-
8
sions or the known benefit-risk profile of 
9
the device. 
10
‘‘(C) 
RELIANCE
ON
SCIENTIFIC
EVI-
11
DENCE.—In considering and taking actions 
12
under this section, the Secretary shall— 
13
‘‘(i) to the extent possible, rely solely 
14
on valid scientific evidence; and 
15
‘‘(ii) in any event, base such actions 
16
on credible scientific evidence, such that 
17
information that is unconfirmed, unreli-
18
able, or lacks sufficient strength of evi-
19
dence shall not constitute an emerging sig-
20
nal or otherwise provide a basis for notifi-
21
cation under this paragraph. 
22
‘‘(D) CONTENT
OF
PUBLIC
NOTIFICA-
23
TION.—Any public notification under this para-
24
graph shall— 
25
23:09 May 03, 2022
H7646
5 
•HR 7646 IH
‘‘(i) include a description of the device 
1
or devices to which the notification applies; 
2
‘‘(ii) reflect a totality of the evidence 
3
on which the notification is based; and 
4
‘‘(iii) incorporate information about 
5
the known benefits and risks of the device 
6
or devices, including information available 
7
from the manufacturer or manufacturers. 
8
‘‘(E) CONTRADICTORY EVIDENCE.—To the 
9
extent credible scientific evidence is presented 
10
to the Secretary that contradicts or modifies 
11
the information that serves as a potential basis 
12
for a public notification under this paragraph, 
13
the Secretary shall include such scientific evi-
14
dence in the public notification in a manner 
15
that provides the intended audience with a com-
16
plete understanding of the overall nature of in-
17
formation concerning the potential risk. 
18
‘‘(F) OPPORTUNITY FOR MANUFACTURERS 
19
TO COMMENT.—Prior to issuance of a public 
20
notification under this paragraph, the Secretary 
21
shall— 
22
‘‘(i) provide the manufacturer or man-
23
ufacturers of the device or devices at issue 
24
the credible scientific evidence that is the 
25
23:09 May 03, 2022
H7646
6 
•HR 7646 IH
basis for considering the public notification 
1
and the Secretary’s initial evaluation of 
2
such evidence as described in subpara-
3
graph (B)(ii); 
4
‘‘(ii) to the extent the Secretary deter-
5
mines that any of the credible scientific 
6
evidence described in clause (i) cannot be 
7
provided to manufacturers because such 
8
evidence constitutes confidential commer-
9
cial information or trade secret informa-
10
tion, provide the manufacturer or manu-
11
facturers of the device or devices at issue 
12
with a description of the withheld evidence 
13
to the extent permissible by law and gen-
14
erally describe the basis for withholding 
15
such evidence; 
16
‘‘(iii) provide the manufacturer or 
17
manufacturers of the device or devices at 
18
issue an adequate opportunity— 
19
‘‘(I) to comment as to the nature 
20
of the potential risk and the manner 
21
and content of the potential notifica-
22
tion under this paragraph; 
23
‘‘(II) to share information about 
24
the potential risk; and 
25
23:09 May 03, 2022
H7646
7 
•HR 7646 IH
‘‘(III) to offer recommendations 
1
as to the form and content of the po-
2
tential notification, including consider-
3
ation of alternative forms of notifica-
4
tion and risk mitigation; and 
5
‘‘(iv) consider any input received 
6
under clause (iii). 
7
‘‘(G) UPDATES.—The Secretary shall pro-
8
vide periodic and timely updates to each notifi-
9
cation under this paragraph based on new in-
10
formation or contrary information, including af-
11
firmative notice in the event that the emerging 
12
signal or other source of potential risk has been 
13
determined not to apply or has otherwise been 
14
resolved or mitigated, such that no additional 
15
actions are required. For purposes of providing 
16
updates under this subparagraph, the Secretary 
17
shall consider information provided to the Sec-
18
retary by a manufacturer subsequent to the ini-
19
tial public notification. 
20
‘‘(H) RESPONSE
TO
INFORMATION
PRO-
21
VIDED BY MANUFACTURER.—With regard to in-
22
formation provided to the Secretary by a manu-
23
facturer relating to a notification under this 
24
23:09 May 03, 2022
H7646
8 
•HR 7646 IH
paragraph, the Secretary shall inform such 
1
manufacturer— 
2
‘‘(i) how such information affects or 
3
alters the Secretary’s initial evaluation; 
4
and 
5
‘‘(ii) whether the notification will be 
6
updated or rescinded as a result of such 
7
information. 
8
‘‘(I) PERIODIC
EVALUATION.—At least 
9
every six months after issuance of a notification 
10
under this paragraph, the Secretary shall— 
11
‘‘(i) evaluate current credible scientific 
12
evidence to determine if such notification 
13
should be rescinded; and 
14
‘‘(ii) if the Secretary determines such 
15
notification should be rescinded, promptly 
16
provide notice of the rescission to the same 
17
audience and in the same manner as the 
18
original notification. 
19
‘‘(J) REVISION OF GUIDANCE.—Not later 
20
than September 30, 2023, the Secretary shall 
21
revise the guidance of the Food and Drug Ad-
22
ministration 
titled 
‘Public 
Notification 
of 
23
Emerging Postmarket Medical Device Signals 
24
23:09 May 03, 2022
H7646
9 
•HR 7646 IH
(‘‘Emerging Signals’’)’, to conform with this 
1
paragraph. 
2
‘‘(K) REPORT
TO
CONGRESS.—Not later 
3
than September 30, 2023, the Secretary shall 
4
submit to the Committee on Energy and Com-
5
merce of the House of Representatives and the 
6
Committee on Health, Education, Labor, and 
7
Pensions of the Senate a report regarding— 
8
‘‘(i) how patients, health care pro-
9
viders, and the public interpret and com-
10
prehend risk-related information provided 
11
or ordered by the Secretary relating to de-
12
vices, including reports under this section, 
13
notifications concerning recalls, and notifi-
14
cations concerning adverse events; and 
15
‘‘(ii) whether the relative level of risk 
16
and appropriate mitigations for such risk 
17
are adequately understood. 
18
‘‘(L) 
THIRD
PARTY
DATA
TRANS-
19
PARENCY.—To the extent the Secretary seeks 
20
to rely on data, analysis, or other information 
21
or findings provided by third parties that has 
22
been funded in whole or in part by, or otherwise 
23
performed under contract with, the Food and 
24
Drug Administration, in making a significant 
25
23:09 May 03, 2022
H7646
10 
•HR 7646 IH
decision concerning one or more devices or con-
1
sidering issuance of an order under this section 
2
or section 522, the Secretary shall— 
3
‘‘(i) obtain access to the raw datasets, 
4
inputs, clinical or other assumptions, meth-
5
ods, analytical code, results, and other 
6
components underlying or comprising the 
7
data, analysis, or other information or 
8
findings upon which the Secretary seeks to 
9
rely; and 
10
‘‘(ii) if such a significant decision is 
11
made, or such an order under this section 
12
or section 522 is under consideration, in 
13
reliance on such data, analysis, or other in-
14
formation or findings, provide the manu-
15
facturer or manufacturers subject to such 
16
decision or order the data, analysis, or 
17
other information or findings, including 
18
the underlying raw datasets, inputs, clin-
19
ical or other assumptions, methods, analyt-
20
ical code, results, and other components, 
21
except that any such raw datasets, inputs, 
22
clinical or other assumptions, methods, an-
23
alytical code, results, and other compo-
24
nents that the Secretary determines to be 
25
23:09 May 03, 2022
H7646
11 
•HR 7646 IH
confidential commercial information or 
1
trade secret information may be withheld 
2
but shall be described to the manufacturer 
3
or manufacturers to the extent permissible 
4
by law.’’. 
5
Æ 
23:09 May 03, 2022
H7646
